APELLIS PHARMACEUTICALS INC (APLS) Fundamental Analysis & Valuation

NASDAQ:APLS • US03753U1060

Current stock price

40.695 USD
+0.06 (+0.16%)
Last:

This APLS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

6

1. APLS Profitability Analysis

1.1 Basic Checks

  • APLS had positive earnings in the past year.
  • APLS had a positive operating cash flow in the past year.
  • APLS had negative earnings in 4 of the past 5 years.
  • In the past 5 years APLS reported 4 times negative operating cash flow.
APLS Yearly Net Income VS EBIT VS OCF VS FCFAPLS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -200M -400M -600M

1.2 Ratios

  • APLS has a better Return On Assets (2.08%) than 88.39% of its industry peers.
  • APLS's Return On Equity of 6.05% is amongst the best of the industry. APLS outperforms 91.10% of its industry peers.
  • APLS has a Return On Invested Capital of 5.83%. This is amongst the best in the industry. APLS outperforms 91.10% of its industry peers.
Industry RankSector Rank
ROA 2.08%
ROE 6.05%
ROIC 5.83%
ROA(3y)-29.1%
ROA(5y)-51.55%
ROE(3y)-117.43%
ROE(5y)-222.36%
ROIC(3y)N/A
ROIC(5y)N/A
APLS Yearly ROA, ROE, ROICAPLS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -200 -400 -600 -800

1.3 Margins

  • APLS has a Profit Margin of 2.23%. This is amongst the best in the industry. APLS outperforms 88.39% of its industry peers.
  • Looking at the Operating Margin, with a value of 5.52%, APLS belongs to the top of the industry, outperforming 89.17% of the companies in the same industry.
  • APLS has a better Gross Margin (89.81%) than 91.68% of its industry peers.
  • In the last couple of years the Gross Margin of APLS has remained more or less at the same level.
Industry RankSector Rank
OM 5.52%
PM (TTM) 2.23%
GM 89.81%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1%
GM growth 5Y-0.05%
APLS Yearly Profit, Operating, Gross MarginsAPLS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -200 -400 -600 -800 -1K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. APLS Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), APLS is destroying value.
  • APLS has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, APLS has more shares outstanding
  • APLS has a better debt/assets ratio than last year.
APLS Yearly Shares OutstandingAPLS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
APLS Yearly Total Debt VS Total AssetsAPLS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

2.2 Solvency

  • An Altman-Z score of 2.37 indicates that APLS is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • APLS has a better Altman-Z score (2.37) than 65.96% of its industry peers.
  • The Debt to FCF ratio of APLS is 10.12, which is on the high side as it means it would take APLS, 10.12 years of fcf income to pay off all of its debts.
  • APLS has a better Debt to FCF ratio (10.12) than 90.52% of its industry peers.
  • A Debt/Equity ratio of 0.98 indicates that APLS is somewhat dependend on debt financing.
  • With a Debt to Equity ratio value of 0.98, APLS is not doing good in the industry: 75.63% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.98
Debt/FCF 10.12
Altman-Z 2.37
ROIC/WACC0.62
WACC9.36%
APLS Yearly LT Debt VS Equity VS FCFAPLS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M -400M

2.3 Liquidity

  • A Current Ratio of 3.14 indicates that APLS has no problem at all paying its short term obligations.
  • With a Current ratio value of 3.14, APLS is not doing good in the industry: 62.09% of the companies in the same industry are doing better.
  • A Quick Ratio of 2.70 indicates that APLS has no problem at all paying its short term obligations.
  • Looking at the Quick ratio, with a value of 2.70, APLS is doing worse than 65.57% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.14
Quick Ratio 2.7
APLS Yearly Current Assets VS Current LiabilitesAPLS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. APLS Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 108.97% over the past year.
  • Looking at the last year, APLS shows a very strong growth in Revenue. The Revenue has grown by 28.46%.
  • APLS shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 31.99% yearly.
EPS 1Y (TTM)108.97%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-62.07%
Revenue 1Y (TTM)28.46%
Revenue growth 3Y137%
Revenue growth 5Y31.99%
Sales Q2Q%-5.94%

3.2 Future

  • APLS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 85.77% yearly.
  • The Revenue is expected to grow by 8.87% on average over the next years. This is quite good.
EPS Next Y-1013.25%
EPS Next 2Y-113.28%
EPS Next 3Y87.13%
EPS Next 5Y85.77%
Revenue Next Year-14.07%
Revenue Next 2Y0.78%
Revenue Next 3Y5.59%
Revenue Next 5Y8.87%

3.3 Evolution

  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
APLS Yearly Revenue VS EstimatesAPLS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 500M 1B 1.5B
APLS Yearly EPS VS EstimatesAPLS Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 -2 4 -4 -6 -8

More info and screens

Find the best growth stocksShow best growing peers

5

4. APLS Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 313.04, which means the current valuation is very expensive for APLS.
  • Based on the Price/Earnings ratio, APLS is valued cheaply inside the industry as 88.39% of the companies are valued more expensively.
  • The average S&P500 Price/Earnings ratio is at 26.21. APLS is valued rather expensively when compared to this.
  • APLS is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE 313.04
Fwd PE N/A
APLS Price Earnings VS Forward Price EarningsAPLS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 100 200 300

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, APLS is valued cheaply inside the industry as 89.56% of the companies are valued more expensively.
  • Based on the Price/Free Cash Flow ratio, APLS is valued cheaply inside the industry as 90.14% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 115.56
EV/EBITDA 90.95
APLS Per share dataAPLS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

  • APLS has a very decent profitability rating, which may justify a higher PE ratio.
  • A more expensive valuation may be justified as APLS's earnings are expected to grow with 87.13% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-113.28%
EPS Next 3Y87.13%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. APLS Dividend Analysis

5.1 Amount

  • No dividends for APLS!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

APLS Fundamentals: All Metrics, Ratios and Statistics

APELLIS PHARMACEUTICALS INC

NASDAQ:APLS (4/7/2026, 3:59:09 PM)

40.695

+0.06 (+0.16%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-24
Earnings (Next)04-30
Inst Owners98.77%
Inst Owner Change0%
Ins Owners4.02%
Ins Owner Change1.38%
Market Cap5.20B
Revenue(TTM)1.00B
Net Income(TTM)22.39M
Analysts71.11
Price Target34.17 (-16.03%)
Short Float %21.35%
Short Ratio8.49
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)8.55%
Min EPS beat(2)-21.01%
Max EPS beat(2)38.1%
EPS beat(4)2
Avg EPS beat(4)-13.31%
Min EPS beat(4)-101.36%
Max EPS beat(4)38.1%
EPS beat(8)5
Avg EPS beat(8)-6.29%
EPS beat(12)6
Avg EPS beat(12)-5.73%
EPS beat(16)7
Avg EPS beat(16)-5.68%
Revenue beat(2)1
Avg Revenue beat(2)4.35%
Min Revenue beat(2)-1.86%
Max Revenue beat(2)10.55%
Revenue beat(4)1
Avg Revenue beat(4)-3.72%
Min Revenue beat(4)-16.4%
Max Revenue beat(4)10.55%
Revenue beat(8)4
Avg Revenue beat(8)-0.96%
Revenue beat(12)7
Avg Revenue beat(12)8.54%
Revenue beat(16)9
Avg Revenue beat(16)6.28%
PT rev (1m)-1.9%
PT rev (3m)-5.7%
EPS NQ rev (1m)5.38%
EPS NQ rev (3m)23.05%
EPS NY rev (1m)0%
EPS NY rev (3m)-6.9%
Revenue NQ rev (1m)0.82%
Revenue NQ rev (3m)5.7%
Revenue NY rev (1m)0.1%
Revenue NY rev (3m)-0.36%
Valuation
Industry RankSector Rank
PE 313.04
Fwd PE N/A
P/S 5.18
P/FCF 115.56
P/OCF 114.77
P/B 14.05
P/tB 14.05
EV/EBITDA 90.95
EPS(TTM)0.13
EY0.32%
EPS(NY)-1.19
Fwd EYN/A
FCF(TTM)0.35
FCFY0.87%
OCF(TTM)0.35
OCFY0.87%
SpS7.85
BVpS2.9
TBVpS2.9
PEG (NY)N/A
PEG (5Y)N/A
Graham Number2.91
Profitability
Industry RankSector Rank
ROA 2.08%
ROE 6.05%
ROCE 7.37%
ROIC 5.83%
ROICexc 15.34%
ROICexgc 15.34%
OM 5.52%
PM (TTM) 2.23%
GM 89.81%
FCFM 4.48%
ROA(3y)-29.1%
ROA(5y)-51.55%
ROE(3y)-117.43%
ROE(5y)-222.36%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1%
GM growth 5Y-0.05%
F-Score7
Asset Turnover0.93
Health
Industry RankSector Rank
Debt/Equity 0.98
Debt/FCF 10.12
Debt/EBITDA 6.35
Cap/Depr 20.09%
Cap/Sales 0.03%
Interest Coverage 1.34
Cash Conversion 79.54%
Profit Quality 201.06%
Current Ratio 3.14
Quick Ratio 2.7
Altman-Z 2.37
F-Score7
WACC9.36%
ROIC/WACC0.62
Cap/Depr(3y)28.62%
Cap/Depr(5y)52.72%
Cap/Sales(3y)0.09%
Cap/Sales(5y)0.79%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)108.97%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-62.07%
EPS Next Y-1013.25%
EPS Next 2Y-113.28%
EPS Next 3Y87.13%
EPS Next 5Y85.77%
Revenue 1Y (TTM)28.46%
Revenue growth 3Y137%
Revenue growth 5Y31.99%
Sales Q2Q%-5.94%
Revenue Next Year-14.07%
Revenue Next 2Y0.78%
Revenue Next 3Y5.59%
Revenue Next 5Y8.87%
EBIT growth 1Y133.6%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-249.58%
EBIT Next 3Y34.89%
EBIT Next 5Y28.94%
FCF growth 1Y151%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y151.59%
OCF growth 3YN/A
OCF growth 5YN/A

APELLIS PHARMACEUTICALS INC / APLS Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for APELLIS PHARMACEUTICALS INC?

ChartMill assigns a fundamental rating of 5 / 10 to APLS.


What is the valuation status of APELLIS PHARMACEUTICALS INC (APLS) stock?

ChartMill assigns a valuation rating of 5 / 10 to APELLIS PHARMACEUTICALS INC (APLS). This can be considered as Fairly Valued.


How profitable is APELLIS PHARMACEUTICALS INC (APLS) stock?

APELLIS PHARMACEUTICALS INC (APLS) has a profitability rating of 6 / 10.


What is the valuation of APELLIS PHARMACEUTICALS INC based on its PE and PB ratios?

The Price/Earnings (PE) ratio for APELLIS PHARMACEUTICALS INC (APLS) is 313.04 and the Price/Book (PB) ratio is 14.05.


Can you provide the financial health for APLS stock?

The financial health rating of APELLIS PHARMACEUTICALS INC (APLS) is 5 / 10.